Artema is a gene therapeutics company focused on the development of gene and cell therapies for hereditary ophthalmological diseases. We invent new therapies for these diseases using the advanced biomedical technologies of genome editing.
Using recombinant AAV viral vectors we develop gene therapies for inherited ophthalmological diseases. We started in 2019 with a gene therapy for our first target eye pathology, which is currently in preclinical trials. Currently, we are working on proof-of-concept of three more AAV-based drugs for inherited pathologies of the eye.
